Answers are grounded in this paper and cite their sources.
Demonstrates conversion of ApoB100 lipoproteins to VLDL in endoplasmic reticulum, highlighting oleic acid's role.
The site where bulk lipid is added to apoB100 low density lipoproteins (LDL)/high density lipoproteins (HDL) particles to form triglyceride-enriched very low density lipoproteins (VLDL) has not been identified definitively. We employed several strategies to address this question. First, McA RH7777 cells were pulse-labeled for 20 min with [35S]methionine/cysteine and chased for 1 h (Chase I) to allow study of newly synthesized apoB100 LDL/HDL remaining in the endoplasmic reticulum (ER). After Chase I, cells were incubated for another hour (C2) with/without brefeldin A (BFA) and nocodazole (Noc) (to block ER to Golgi trafficking) and with/without oleic acid (OA). OA treatment alone during C2 increased VLDL secretion. This was prevented by the addition of BFA/Noc in C2. When C2 media were replaced by control media for another 1-h chase (C3), VLDL formed during OA treatment in C2 were secreted into C3 medium. Thus, OA-induced conversion of apoB100 LDL/HDL to VLDL during C2 occurred in the ER. Next, newly synthesized apoB100 lipoproteins were trapped in the Golgi by treatment with Noc and monensin during Chase I (C1), and C2 was carried out in the presence of BFA/Noc with/without OA and without monensin. Under these conditions, OA treatment during C2 did not stimulate VLDL secretion. The same pulse/chase protocols were followed by iodixanol subcellular fractionation, extraction of lipoproteins from ER and Golgi, and sucrose gradient separation of extracted lipoproteins. Cells treated with BFA/Noc and OA in C2 had VLDL in the ER. In the absence of OA, only LDL/HDL were present in the ER. The density of Golgi lipoproteins in these cells was not affected by OA. Similar results were obtained when ER were immuno-isolated with anti-calnexin antibodies. In conclusion, apoB100 bulk lipidation, resulting in conversion of LDL/HDL to VLDL, can occur in the ER, but not in the Golgi, in McA RH7777 cells. The site where bulk lipid is added to apoB100 low density lipoproteins (LDL)/high density lipoproteins (HDL) particles to form triglyceride-enriched very low density lipoproteins (VLDL) has not been identified definitively. We employed several strategies to address this question. First, McA RH7777 cells were pulse-labeled for 20 min with [35S]methionine/cysteine and chased for 1 h (Chase I) to allow study of newly synthesized apoB100 LDL/HDL remaining in the endoplasmic reticulum (ER). After Chase I, cells were incubated for another hour (C2) with/without brefeldin A (BFA) and nocodazole (Noc) (to block ER to Golgi trafficking) and with/without oleic acid (OA). OA treatment alone during C2 increased VLDL secretion. This was prevented by the addition of BFA/Noc in C2. When C2 media were replaced by control media for another 1-h chase (C3), VLDL formed during OA treatment in C2 were secreted into C3 medium. Thus, OA-induced conversion of apoB100 LDL/HDL to VLDL during C2 occurred in the ER. Next, newly synthesized apoB100 lipoproteins were trapped in the Golgi by treatment with Noc and monensin during Chase I (C1), and C2 was carried out in the presence of BFA/Noc with/without OA and without monensin. Under these conditions, OA treatment during C2 did not stimulate VLDL secretion. The same pulse/chase protocols were followed by iodixanol subcellular fractionation, extraction of lipoproteins from ER and Golgi, and sucrose gradient separation of extracted lipoproteins. Cells treated with BFA/Noc and OA in C2 had VLDL in the ER. In the absence of OA, only LDL/HDL were present in the ER. The density of Golgi lipoproteins in these cells was not affected by OA. Similar results were obtained when ER were immuno-isolated with anti-calnexin antibodies. In conclusion, apoB100 bulk lipidation, resulting in conversion of LDL/HDL to VLDL, can occur in the ER, but not in the Golgi, in McA RH7777 cells. Although the early, crucial steps in apolipoprotein B100 (apoB100)-lipoprotein assembly, including translation, translocation, and targeting of apoB100 for the ubiquitin-proteasomal degradation pathway have been well studied (1Fisher E.A. Ginsberg H.N. J. Biol. Chem. 2002; 277: 17377-17380Abstract Full Text Full Text PDF PubMed Scopus (379) Google Scholar), much less is known about how the mature, triglyceride (TG) 1The abbreviations used are: TG, triglyceride; ALLN, N-acetyl-Leu-Leu-norleucinal; LDL, low density lipoprotein; HDL, high density lipoprotein; VLDL, very low density lipoprotein; ER, endoplasmic reticulum; MTP, microsomal triglyceride transfer protein; OA, oleic acid; BFA, brefeldin A; Noc, nocodazole; Mon, monensin; [35S]Met, [35S]methionine/cysteine; MEM, minimum essential medium; BSA, bovine serum albumin.-enriched lipoprotein is assembled. Thus, the exact process of bulk lipid addition and, in particular, the site where bulk lipid is added to apoB100 low density lipoproteins (LDL)/high density lipoproteins (HDL) to form mature, TG-enriched very low density lipoproteins (VLDL) has not been identified definitively. Early work by Hamilton and co-workers using electron microscopy (2Alexander C.A. Hamilton R.L. Havel R.J. J. Cell Biol. 1976; 69: 241-263Crossref PubMed Scopus (253) Google Scholar), suggests that a lipid-poor form of apoB present in the rough endoplasmic reticulum (ER) could fuse with lipid droplets present in the smooth ER. That work first raised the possibility that VLDL was assembled in a two-step process. This scheme has been supported by studies from several laboratories (3Rustaeus S. Lindberg K. Stillemark P. Claesson C. Asp L. Larsson T. Boren J. Olofsson S.-O. J. Nutr. 1999; 129: 463-466Crossref PubMed Google Scholar, 4Olofsson S.-O. Stillemark-Billton P. Asp L. Trends Cardiovasc. Med. 2000; 10: 338-345Crossref PubMed Scopus (106) Google Scholar, 5Tran K. Thorne-Tjomsland G. DeLong C.J. Cui Z. Shan J. Burton L. Jamieson J.C. Yao Z. J. Biol. Chem. 2002; 277: 31187-31200Abstract Full Text Full Text PDF PubMed Scopus (85) Google Scholar), including our own (6Pan M. Liang J.-S. Fisher E.A. Ginsberg H.N. J. Biol. Chem. 2002; 277: 4413-4421Abstract Full Text Full Text PDF PubMed Scopus (49) Google Scholar). The two-step model includes the transformation of an “HDL-like” apoB-lipoprotein to a TG-enriched lipoprotein in the presence of adequate cell lipid stores (4Olofsson S.-O. Stillemark-Billton P. Asp L. Trends Cardiovasc. Med. 2000; 10: 338-345Crossref PubMed Scopus (106) Google Scholar, 7Ginsberg H.N. Curr. Opin. Lipidol. 1995; 6: 275-280Crossref PubMed Scopus (72) Google Scholar). Microsomal triglyceride transfer protein (MTP) activity is required before and during the early stages of apoB-lipoprotein assembly in order for bulk lipid addition to occur at the later stages (1Fisher E.A. Ginsberg H.N. J. Biol. Chem. 2002; 277: 17377-17380Abstract Full Text Full Text PDF PubMed Scopus (379) Google Scholar, 8Gordon D.A. Jamil H. Biochim. Biophys. Acta. 2000; 1486: 72-83Crossref PubMed Scopus (191) Google Scholar, 9Wang Y. Tran K. Yao Z. J. Biol. Chem. 1999; 274: 27793-27800Abstract Full Text Full Text PDF PubMed Scopus (117) Google Scholar, 10Wang Y McLeod R.S. Yao Z. J. Biol. Chem. 1997; 272: 12272-12278Abstract Full Text Full Text PDF PubMed Scopus (86) Google Scholar). Raabe et al. (11Raabe M. Veniant M.M. Sullivan M.A. Zlot C.H. Jorkegren J. Nielsen L.B. Wong J.S. Hamilton R.L. Young S.G. J. Clin. Invest. 1999; 103: 1287-1298Crossref PubMed Scopus (362) Google Scholar) find an absence of lipid droplets in either ER or Golgi in MTP-deficient mice and conclude that MTP was required to deliver bulk lipid to a site where it could be added to HDL-like apoB lipoproteins. On the other hand, our recent studies indicate that the actual addition of bulk lipid during the final stage of assembly is independent of both MTP activity and ongoing TG (6Pan M. Liang J.-S. Fisher E.A. Ginsberg H.N. J. Biol. Chem. 2002; 277: 4413-4421Abstract Full Text Full Text PDF PubMed Scopus (49) Google Scholar). for an of lipid with lipid droplets can be in the very recent study by et al. S. J. Biol. Chem. 2002; 277: Full Text Full Text PDF PubMed Scopus Google Scholar). a the model for a two-step assembly of VLDL, the site at the studies that transformation either of apoB to a of the ER or of apoB from to another (4Olofsson S.-O. Stillemark-Billton P. Asp L. Trends Cardiovasc. Med. 2000; 10: 338-345Crossref PubMed Scopus (106) Google Scholar, P. Boren J. M. Larsson T. S. Olofsson S.-O. J. Biol. Chem. 2000; Full Text Full Text PDF PubMed Scopus Google Scholar, L. Claesson C. Boren J. Olofsson S.-O. J. Biol. Chem. 2000; Full Text Full Text PDF PubMed Scopus Google Scholar), but a of the that this (2Alexander C.A. Hamilton R.L. Havel R.J. J. Cell Biol. 1976; 69: 241-263Crossref PubMed Scopus (253) Google Scholar, 5Tran K. Thorne-Tjomsland G. DeLong C.J. Cui Z. Shan J. Burton L. Jamieson J.C. Yao Z. J. Biol. Chem. 2002; 277: 31187-31200Abstract Full Text Full Text PDF PubMed Scopus (85) Google Scholar, J. J. Biol. Chem. Full Text PDF PubMed Google Scholar, S. PubMed Scopus Google Scholar, PubMed Scopus Google Scholar, H. J. Cell Biol. PubMed Scopus Google Scholar, J. 1995; Full Text PDF PubMed Google Scholar, K. C. C. J. Full Text Full Text PDF PubMed Google Scholar). In the studies using and subcellular that the oleic acid conversion of apoB100 particles to VLDL in McA RH7777 cells in the ER and not in the bovine serum brefeldin A (BFA) at nocodazole (Noc) at 20 and monensin at were from was used to block ER to Golgi Noc was used to Golgi into ER, and was used to block from the Golgi to the S. Ginsberg H.N. J. Biol. Chem. Full Text PDF PubMed Google Scholar). apoB100 were from anti-calnexin was from and protein were from iodixanol was obtained from was from was from essential was from of RH7777 obtained from were in with The cells were in and serum studies the was to and other McA RH7777 cells were in for 1 h followed by with with or without for 1 h and with BSA, with/without ALLN, and for 20 was followed by or chase chase was min was used for chase the was at the of chase and used for sucrose density gradient Cells were either for or for cell were to a of of 1 and was added to the Cells were with and of apoB100 in or was carried out to the of et al. S. Ginsberg H.N. J. Biol. Chem. Full Text PDF PubMed Google Scholar). was added to the to was later by the for were with The was treated with and, to at gradient of lipoproteins was by Boren et al. J. S. Olofsson S.-O. J. Biol. Chem. Full Text PDF PubMed Google Scholar). the sucrose gradient was formed by from the of the of of of in and of 1 ALLN, and The were at in a for h at and were from the to the in were to J.-S. H. M. H. P. Ginsberg H.N. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). A of iodixanol was by of with 1 of sucrose and The were to iodixanol by of the with 1 of the and in were carried out in a at and for h with and the during from were first in ER and Golgi were by of using anti-calnexin and of from was by et al. S. Stillemark P. Lindberg K. Olofsson S.-O. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). ER or Golgi were with of 1 sucrose and of in The was incubated for min at of was added to a final of and the was for After the the extracted was to and for sucrose gradient of were used for by with an anti-calnexin at for 1 is an ER protein is the of the ER, this be of from the ER. In that but not was present in the immuno-isolated The were by with protein were extracted from the by the of et al. S. Stillemark P. Lindberg K. Olofsson S.-O. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar) The extracted protein was to and and to sucrose gradient LDL/HDL That in the ER be to VLDL by our the site where bulk lipid is added to apoB100 LDL/HDL particles to form mature, TG-enriched VLDL, McA RH7777 cells were pulse-labeled for 20 min with [35S]Met, and the was chased for 1 h (Chase I in the presence of a our this of a of newly synthesized apoB100 in the ER that can later be to VLDL by the addition of OA to the media (6Pan M. Liang J.-S. Fisher E.A. Ginsberg H.N. J. Biol. Chem. 2002; 277: 4413-4421Abstract Full Text Full Text PDF PubMed Scopus (49) Google Scholar). apoB is present in the VLDL, LDL, and After media were and cells were incubated in media for another hour (Chase with/without and nocodazole (Noc) and with/without OA The of was added min before the addition of OA, was used to block ER to Golgi and Golgi into ER S. Ginsberg H.N. J. Biol. Chem. Full Text PDF PubMed Google Scholar). C2 media were at the of C2 and used for sucrose density gradient In the absence of during C2 apoB100 was secreted lipoproteins with a of including VLDL and OA treatment alone during C2 a in of the of but VLDL with control cells to first treatment of cells with only BFA/Noc during C2 in of only a of apoB100 LDL/HDL particles apoB100 when it is added to the media S. Ginsberg H.N. J. Biol. Chem. Full Text PDF PubMed Google Scholar) in the present studies not apoB100 LDL/HDL secreted in the presence of BFA/Noc during C2 apoB100 lipoproteins that had the ER during but had not been secreted by the C2 was treatment of cells with both OA and BFA/Noc in C2 in the same of of apoB100 LDL/HDL particles with BFA/Noc alone with results that when apoB100 lipoproteins were trapped in the ER during C2 by OA treatment could not stimulate the of apoB100 VLDL OA did not stimulate the conversion of apoB100 LDL/HDL that had the ER to our in a study (6Pan M. Liang J.-S. Fisher E.A. Ginsberg H.N. J. Biol. Chem. 2002; 277: 4413-4421Abstract Full Text Full Text PDF PubMed Scopus (49) Google Scholar) that obtained results with or without in the these studies in the absence of The results in to in Thus, the addition of a of newly synthesized apoB100 from early degradation did not the of either OA or BFA/Noc of ER to Golgi OA treatment during C2 had the addition of bulk to apoB100 lipoproteins that were trapped in the ER during that the was but at the of the BFA/Noc or without that was present during C2 was to chase without either BFA/Noc or OA, and the cells were incubated for an min (Chase This chase have apoB100 lipoproteins that had been trapped in the ER during C2 to be In cells treated with BFA/Noc but without OA in with during C3 in of a of apoB100 LDL/HDL A and OA treatment with BFA/Noc during C2 in the during C3 of increased of apoB100 lipoprotein that had from LDL/HDL to VLDL and A and the same results were BFA/Noc OA in C2 by only min or min The with BFA/Noc was to that both of had to block (BFA) and (Noc) of ER and Golgi before OA was the in was without present at The in were to in A and the results of the in indicate that apoB100 LDL/HDL that were to OA trapped in the ER by BFA/Noc during C2 could be secreted VLDL particles the BFA/Noc had been at the of in of the of of the of the studies in 1 and was present in other to degradation of newly synthesized apoB100 and the of for was using the In this in apoB100 in the media was density gradient First, that the presence of OA in C2 was with of apoB100 lipoproteins during C3 with when OA was in C2 to that the presence of BFA/Noc during C3 the presence or absence of OA in results in of apoB100 lipoproteins. results our that when BFA/Noc were from the media C2 A and was secreted during C3 had to have from the ER. LDL/HDL That in the Golgi to VLDL by the in of BFA/Noc to block to that OA could apoB100 LDL/HDL that were trapped in the ER into apoB100 VLDL that could be secreted when BFA/Noc were studies were not to the of OA apoB100 lipoproteins in the in the apoB100 LDL/HDL that was in the Golgi could be to VLDL by OA. The in A and that was not the but to this in used Noc and treatment to newly synthesized apoB100 lipoproteins in the Golgi during Under these conditions, apoB100 lipoproteins were secreted into the media during not The was to BFA/Noc but for the min Under this of apoB100 lipoproteins from the ER to the Golgi be be C2 was carried out in either the presence or absence OA. Under these conditions, the presence of OA during C2 had the density of the secreted apoB100 the same of VLDL, LDL, and was secreted A and results that when apoB100 lipoproteins were first trapped in the Golgi and and the addition of OA at the of could not stimulate the conversion of apoB100 LDL/HDL particles to LDL/HDL to VLDL in the ER by from studies used of protein and secreted apoB100 lipoproteins. The same pulse/chase in 1 was employed to allow of apoB100 lipoproteins from ER and After cells were by and were The were to iodixanol subcellular fractionation, extraction of lipoproteins from ER and Golgi and sucrose gradient separation of extracted lipoproteins. used a of the ER, was present in of the iodixanol used a of Golgi, was present in were for extraction of lipoproteins in the ER, and were for extraction of lipoproteins in the In the absence of OA, apoB100 lipoproteins from ER that had been treated with only BFA/Noc were at the density of LDL/HDL treatment with OA and BFA/Noc a of apoB100 lipoproteins from the ER to a density to with a but conversion of LDL/HDL to VLDL particles the density of apoB100 lipoproteins in the Golgi from these same cells was not affected by treatment with Golgi from control cells conclude that apoB lipoproteins from the Golgi in this had before the addition of Although of apoB lipoproteins were secreted during C2 were in the Golgi, and were not affected by the presence of OA. results from studies in indicate that apoB lipoproteins that have been secreted from the Golgi during C2 in this in the presence of BFA/Noc have been LDL/HDL in these results with the obtained from the cell in secreted lipoproteins were and that the conversion of apoB100 LDL/HDL to apoB100 VLDL in to OA in the ER. LDL/HDL to VLDL in the ER by from our used an to the of OA apoB100 lipoproteins in the ER. In these cells were C2 and ER from by using an anti-calnexin In that the by alone both and by of the immuno-isolated ER only of The of in the immuno-isolated ER were to obtained when cells were to subcellular by iodixanol in the presence of with OA during C2 the conversion of apoB100 LDL/HDL to apoB100 VLDL in the ER. study by the assembly of VLDL by the that study is the process lipid-poor apoB100 LDL/HDL particles into and has been in of a model in assembly of VLDL is a two-step process (2Alexander C.A. Hamilton R.L. Havel R.J. J. Cell Biol. 1976; 69: 241-263Crossref PubMed Scopus (253) Google Scholar, S. Lindberg K. Stillemark P. Claesson C. Asp L. Larsson T. Boren J. Olofsson S.-O. J. Nutr. 1999; 129: 463-466Crossref PubMed Google Scholar, 4Olofsson S.-O. Stillemark-Billton P. Asp L. Trends Cardiovasc. Med. 2000; 10: 338-345Crossref PubMed Scopus (106) Google Scholar, 5Tran K. Thorne-Tjomsland G. DeLong C.J. Cui Z. Shan J. Burton L. Jamieson J.C. Yao Z. J. Biol. Chem. 2002; 277: 31187-31200Abstract Full Text Full Text PDF PubMed Scopus (85) Google Scholar, M. Liang J.-S. Fisher E.A. Ginsberg H.N. J. Biol. Chem. 2002; 277: 4413-4421Abstract Full Text Full Text PDF PubMed Scopus (49) Google Scholar). The site of this the of several the studies conclude that lipid-poor apoB100 lipoproteins can be from particles in the LDL/HDL to VLDL density lipoproteins in the ER but not in the results of secreted apoB100 lipoproteins from the media well from OA-induced conversion of apoB100 LDL/HDL to VLDL in ER by independent On the other hand, our of of apoB100 lipoprotein including of the degradation pathway well of of be is to a for our First, our of to degradation was the that the the of lipid-poor apoB100 lipoproteins in the ER at the of a of particles to In our study had that this newly synthesized apoB100 in a microsomal in lipoproteins in the LDL/HDL (6Pan M. Liang J.-S. Fisher E.A. Ginsberg H.N. J. Biol. Chem. 2002; 277: 4413-4421Abstract Full Text Full Text PDF PubMed Scopus (49) Google Scholar). The results of the in 1 and that the presence of did not the of Thus, that the presence of during the our to without a of the for our of of steps in the pathway was from several laboratories that from the ER is the in apoB100 lipoprotein from the cell K. Thorne-Tjomsland G. DeLong C.J. Cui Z. Shan J. Burton L. Jamieson J.C. Yao Z. J. Biol. Chem. 2002; 277: 31187-31200Abstract Full Text Full Text PDF PubMed Scopus (85) Google Scholar, J. Biol. Chem. Full Text PDF PubMed Google Scholar). studies and our own results that the with apoB100 lipoproteins the ER and the cell the ER it to in either the ER or the by steps in the pathway with BFA/Noc or to apoB100 lipoproteins in either the ER or Golgi, at the of C2 before added OA. This to lipoproteins from either media or at the of C2 or from the media at the of C3 the pathway from the activity of the The of a in our studies be with the studies by et al. S. Lindberg K. Boren J. Olofsson J. Biol. Chem. 1995; Full Text Full Text PDF PubMed Scopus Google Scholar), in of much used and to block of from the ER the assembly of both apoB100 and VLDL in McA RH7777 cells. In the before and the by added only min the and at a when apoB100 had lipid to be in LDL/HDL particles (6Pan M. Liang J.-S. Fisher E.A. Ginsberg H.N. J. Biol. Chem. 2002; 277: 4413-4421Abstract Full Text Full Text PDF PubMed Scopus (49) Google Scholar). et al. S. Lindberg K. Boren J. Olofsson J. Biol. Chem. 1995; Full Text Full Text PDF PubMed Scopus Google Scholar) that the of were it was from the that could our in where VLDL secreted during C3 from cells treated with OA and BFA/Noc during C2. On the other were to VLDL from the ER of cells treated with OA and BFA/Noc during C2 without and et al. Y. Tran K. Yao Z. J. Biol. Chem. 1999; 274: 27793-27800Abstract Full Text Full Text PDF PubMed Scopus (117) Google Scholar) that low treatment of McA RH7777 cells VLDL assembly in the ER, it did not the of TG into the of the ER. Thus, the lipid for the conversion of apoB100 LDL/HDL to apoB100 VLDL have in the ER during C2 in our studies the presence of that in the conditions, the when was added to the can the in of in our studies with of et al. S. Lindberg K. Boren J. Olofsson J. Biol. Chem. 1995; Full Text Full Text PDF PubMed Scopus Google Scholar). On the other hand, studies our of using to block of out of the ER. the present results with in this electron microscopy studies by Hamilton and co-workers (2Alexander C.A. Hamilton R.L. Havel R.J. J. Cell Biol. 1976; 69: 241-263Crossref PubMed Scopus (253) Google Scholar) indicate that the smooth ER be the site of VLDL a study by et al. J. J. Biol. Chem. Full Text PDF PubMed Google Scholar) that lipoprotein was in the ER. Similar have been in studies of lipoprotein in J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). On the other hand, early studies that the final of the apoB lipoprotein in the Golgi S. PubMed Scopus Google Scholar, PubMed Scopus Google Scholar). et al. H. J. Cell Biol. PubMed Scopus Google Scholar), using electron that Golgi lipoproteins were of the of VLDL, in the ER were recent studies in by et al. J. 1995; Full Text PDF PubMed Google Scholar, K. C. C. J. Full Text Full Text PDF PubMed Google Scholar) indicate that addition of to apoB lipoproteins could occur in the work by Tran et al. K. Thorne-Tjomsland G. DeLong C.J. Cui Z. Shan J. Burton L. Jamieson J.C. Yao Z. J. Biol. Chem. 2002; 277: 31187-31200Abstract Full Text Full Text PDF PubMed Scopus (85) Google Scholar) subcellular that the of apoB100 VLDL assembly occurred in the studies by Stillemark et al. P. Boren J. M. Larsson T. S. Olofsson S.-O. J. Biol. Chem. 2000; Full Text Full Text PDF PubMed Scopus Google Scholar) and Asp et al. L. Claesson C. Boren J. Olofsson S.-O. J. Biol. Chem. 2000; Full Text Full Text PDF PubMed Scopus Google Scholar) of the OA-induced conversion of an VLDL in McA RH7777 cells but did not the site of the bulk addition of studies that the addition of bulk lipid required from the rough ER to a but could not the smooth ER, the known the ER Golgi or the early (4Olofsson S.-O. Stillemark-Billton P. Asp L. Trends Cardiovasc. Med. 2000; 10: 338-345Crossref PubMed Scopus (106) Google Scholar). did not the of apoB100 that is the form of apoB lipoproteins. We that the of the site of VLDL assembly from of apoB100 the pathway it from a of lipid-poor lipoproteins to a of mature, lipoproteins. studies have that apoB100 to and with in the for a of M. H. Ginsberg H.N. Fisher E.A. S. PubMed Scopus Google Scholar, H. Ginsberg H.N. Fisher E.A. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar) a lipid-poor lipoprotein with a density of LDL/HDL (6Pan M. Liang J.-S. Fisher E.A. Ginsberg H.N. J. Biol. Chem. 2002; 277: 4413-4421Abstract Full Text Full Text PDF PubMed Scopus (49) Google Scholar). OA is added to the these lipid-poor apoB100 LDL/HDL to fuse with lipid droplets in the of the ER (2Alexander C.A. Hamilton R.L. Havel R.J. J. Cell Biol. 1976; 69: 241-263Crossref PubMed Scopus (253) Google Scholar, S. J. Biol. Chem. 2002; 277: Full Text Full Text PDF PubMed Scopus Google Scholar, M. Fisher E.A. Ginsberg H.N. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar) and secreted VLDL M. H. Ginsberg H.N. Fisher E.A. S. PubMed Scopus Google Scholar, H. Ginsberg H.N. Fisher E.A. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). We that the recent results of Tran et al. K. Thorne-Tjomsland G. DeLong C.J. Cui Z. Shan J. Burton L. Jamieson J.C. Yao Z. J. Biol. Chem. 2002; 277: 31187-31200Abstract Full Text Full Text PDF PubMed Scopus (85) Google Scholar) to the of apoB100 VLDL Thus, in the absence of that can apoB lipoproteins in the both and the site of of not the site of The of apoB the pathway by and J. Biol. Chem. Full Text PDF PubMed Google Scholar) and in our own studies to apoB100 lipoproteins in In our studies were to the of OA the density of apoB100 lipoproteins that had been trapped in subcellular by treatment of cells with of in the ER by BFA/Noc or in the Golgi by We apoB100 lipoproteins secreted of the well apoB100 lipoproteins from ER and Golgi during results that OA treatment was to stimulate the of apoB100 VLDL particles in the presence of OA of could be BFA/Noc was with the of from ER cells had been to BFA/Noc and OA that OA the conversion of to apoB100 VLDL in the ER. from the ER to the of the and early can occur in the presence of with the Golgi is and the to the ER J. J.S. Full Text PDF PubMed Scopus Google Scholar). our studies that were trapped in the Golgi, OA could not conversion to with the absence of for the conversion of apoB100 lipoproteins to apoB100 VLDL in our Golgi to conclude that the Golgi is not the site of bulk addition of to lipid-poor apoB100
No takes yet. Share an insight, caveat, or question.
Yamaguchi et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: